Cancer Causes Stable Laws

Rick Durrett

... 

A report on joint work
with Stephen Moseley (Cornell → consulting in Boston)
with Jasmine Foo, Kevin Leder (Minnesota),
Franziska Michor (Dana Farber Cancer Institute),
and John Mayberry (Cornell postdoc → U. of the Pacific),
and with Kaveh Danesh (Duke Undergraduate)
Laura Havrilesky and Evan Myers
(Obstetrics and Gynecology, Duke Medical Center).
Stan Ulam once said:

“I have sunk so low that my last paper contained numbers with decimal points.”

Figure: Feynman, Ulam, von Neumann
Armitage and Doll (1954)

Noticed that log-log plots of cancer incidence data are linear for a large number of cancer types; for example, colorectal cancer incidence has a slope of 5.18 in men and 4.97 in women.
Multi-stage theory of carcinogenesis

Armitage and Doll (1954) use the observation that the slopes were 5.18 in men and 4.97 in women to argue that colon cancer is a six stage process. The math was very simple

Suppose $X_i$ are independent and have an exponential distribution with rates $u_i$. The sum $X_1 + \cdots + X_k$ has a density function that is asymptotically

$$u_1 \cdots u_k \frac{t^{k-1}}{(k-1)!} \quad \text{as } t \to 0$$
Incidence of Retinoblastoma

Knudson’s two hit hypothesis → tumor-suppressor genes

Nature Reviews Cancer

Fraction of cases not yet diagnosed vs. Age (months)
Progression to Colon Cancer

Luebeck and Moolgavakar (2002) PNAS fit a four stage model to incidence of colon cancer by age.
What are the stages?

- In sporadic cases of colon cancer the first two stages are inactivation of the tumor suppressor gene APC adenomatous polyposis coli.
- KRAS is an oncogene (one mutation turns it on). Once it is turned on it recruits and activates proteins necessary for the propagation of growth factor.
- The final stage is thought to involve the inactivation of TP53 the gene which makes p53. Mutant p53 can no longer bind DNA in an effective way, and as a consequence the p21 protein whose production it stimulates is not made available to act as the ’stop signal’ for cell division.
Things are not so simple

- In 20% of colon cancers, \( APC \) is not mutated but instead the oncogene \( \beta \)-catenin (in the same pathway) is. This and other examples suggest that features of the disease are due to disrupting certain molecular pathways not necessarily specific mutations.

- One of the main aims of large scale sequencing of cancer tumors is to find mutations that are potential drug targets. However many statistically significant mutations are “passengers” that occurred on the same chromosome with a causative mutation.

- Even when mutations are declared to be causative on statistical grounds, the tumor subtypes they define do not correlate well with the behavior of the disease and its response to treatment.
Multitype Markovian binary branching process

\[ Z_i(t) \equiv \text{the number of type } i \text{ cells} \]

Type \( i \) cell give birth at rate \( a_i \) and die at rate \( b_i \).

\textbf{Yes we have deaths at rate } b. \textbf{.}

Type \( i \) cells produce offspring of type \( i + 1 \) at rate \( u_{i+1} \).
Type 0's are a branching process

Birth at rate $a_0$, death at rate $b_0$, $\lambda_0 = a_0 - b_0$.

$$P(Z_0(t) = 0 \text{ for some } t \geq 0) = \frac{b_0}{a_0}$$

As $t \to \infty$, $e^{-\lambda_0 t}Z_0(t) \to W_0$ a.s.

$$W_0 = \frac{b_0}{a_0} \delta_0 + \frac{\lambda_0}{a_0} \text{ exponential}(\lambda_0/a_0)$$

exponential($r$) has density $re^{-rt}$, mean $1/r$.

If we condition on nonextinction the limit is exponential($\lambda_0/a_0$).
Type 1’s: Durrett and Moseley (2009)

\[ M_t = e^{-\lambda_1 t}Z_1(t) - \int_0^t u_1 e^{-\lambda_1 s}Z_0(s) \, ds \] is a martingale.

**Theorem 2.** As \( t \to \infty \), \( e^{-\lambda_1 t}Z_1(t) \to W_1 \) a.s. with

\[ EW_1 = u_1/(\lambda_1 - \lambda_0) \]
Type 1’s: Durrett and Moseley (2009)

\[ M_t = e^{-\lambda_1 t} Z_1(t) - \int_0^t u_1 e^{-\lambda_1 s} Z_0(s) \, ds \] is a martingale.

**Theorem 2.** As \( t \to \infty \), \( e^{-\lambda_1 t} Z_1(t) \to W_1 \) a.s. with

\[ EW_1 = u_1 / (\lambda_1 - \lambda_0) \]

Let \( Z_1^*(t) \) be the number of 1’s when \( Z_0^*(t) = V_0 e^{\lambda_0 t} \), \( t \in (-\infty, \infty) \).

**Theorem 3.** As \( t \to \infty \), \( e^{-\lambda_1 t} Z_1^*(t) \to V_1 \) a.s. with

\[ E(\exp(-\theta V_1)|V_0) = \exp(-c_{h,1} u_1 V_0 \theta^{\alpha_1}) \]

and \( \alpha_1 = \lambda_0 / \lambda_1 \). \((V_1|V_0)\) is one sided stable law with index \( \alpha_1 \in (0, 1) \).
Growth rate of type $k$’s

Suppose $Z_0^*(t) = V_0 e^{\lambda_0 t}$ for $t \in (-\infty, \infty)$ where $V_0$ is exponential($\lambda_0/a_0$).

$$e^{-\lambda_k t} Z_k^*(t) \rightarrow V_k \quad a.s.$$

Let $\mathcal{F}_{\infty}^{k-1}$ be the $\sigma$-field generated by $Z_j^*(t), j \leq k-1, t \geq 0.$

$$E(e^{-\theta V_k}|\mathcal{F}_{\infty}^{k-1}) = \exp(-c_{h,k} u_k V_{k-1} \theta^{\alpha_k})$$

where $\alpha_k = \lambda_{k-1}/\lambda_k$ and hence $E e^{-\theta V_k} = (1 + c_{\theta,k} \mu_k \theta^{\lambda_0/\lambda_k})^{-1}$.

$$c_{h,k} = \frac{1}{a_k} \left( \frac{a_k}{\lambda_k} \right)^{\alpha_k} \Gamma(\alpha_k) \Gamma(1 - \alpha_k)$$

$$c_{\theta,k} = c_{\theta,k-1} c_{h,k}^{\lambda_0/\lambda_{k-1}}, c_{\theta,0} = a_0/\lambda_0 \text{ and } \mu_k = \prod_{j=1}^{k} u_j^{\lambda_0/\lambda_{j-1}}.$$
Transitions between waves

\[ z_k(t) = \frac{1}{L} \log^+ Z_k(t) \approx \lambda_k (t - \beta_k)^+ \quad L = \log(1/u) \quad \beta_k = \sum_{j=0}^{k-1} \frac{1}{\lambda_j} \]

\[ z_0(t) \quad z_1(t) \quad z_2(t) \]

Population size $1/u$

Studied mutational waves in a Moran model with an exponentially growing population. For theorems see D+Mayberry AoAP 21 (2011), 699–744
Ovarian Cancer

Ovarian cancer is the fifth leading cause of cancer death among women in the United States.

21,800 new cases and 13,850 deaths in 2010.
Can screening reduce mortality?

In the June 8, 2011 issue of the JAMA, results were published of a study of 78,216 women aged 55–74. Screening used tests for the bio-marker CA125 (cancer antigen) and transvaginal ultrasound.

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>diagnosed</th>
<th>death</th>
</tr>
</thead>
<tbody>
<tr>
<td>annual screening</td>
<td>39,105</td>
<td>212</td>
<td>118</td>
</tr>
<tr>
<td>routine care</td>
<td>39,111</td>
<td>176</td>
<td>100</td>
</tr>
</tbody>
</table>
Can screening reduce mortality?

In the June 8, 2011 issue of the JAMA, results were published of a study of 78,216 women aged 55–74. Screening used tests for the bio-marker CA125 (cancer antigen) and transvaginal ultrasound.

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>diagnosed</th>
<th>death</th>
</tr>
</thead>
<tbody>
<tr>
<td>annual screening</td>
<td>39,105</td>
<td>212</td>
<td>118</td>
</tr>
<tr>
<td>routine care</td>
<td>39,111</td>
<td>176</td>
<td>100</td>
</tr>
</tbody>
</table>

3,285 women in the screening group had false positive results, 1080 had surgery and 163 had serious complications from surgery.
An epidermal to mesenchymal transition in the tumor allows its cells to detach. Cells float in the peritoneal fluid as single cells or small groups. Some cells adhere to the omentum, followed by invasion of the extracellular matrix, angiogenesis etc. There are no significant genetic differences between the main tumor and metastases indicating that no additional mutations are needed beyond those that created the initial tumor.

type 0 = primary tumor, type 1 = metastasis. $u_1 =$ rate at which cells leave tumor and attach to the omentum.


$\lambda_0 = (\ln 2)/4$, $\lambda_1 = (\ln 2)/2.5$ per month, $u_1 =$ ?
Brown and Palmers’ parameter estimation

**Figure:** A. Growth in stages I and II, B. Stages III and IV.
What is the detection window?

People tell us that $1\text{cm}^3 = 10^9$ cells.

Why is this true? $1\text{cm}^3 = 1$ gram. Cells are mostly water. 10 trillion cells ($10^{13}$) in the human body (and 100 million microbes live on or in us according to Susan Holmes) 100 Kilograms $= 10^5$, which gives $1\text{cm}^3 = 10^8$ cells.

Let $T_0$ be the time the primary tumor (type 0) has a diameter of 0.5 cm, corresponding to $Z_0(t) = 6.5 \times 10^7$ cells. $V = (\pi/6)d^3$.

At this point it would be hard to detect by transvaginal ultrasound.

Let $T_1$ be the time that there are $Z_1(t) = 10^9$ metastatic cells (one gram).
Size of the detection window

\[ Z_0(t) = e^{\lambda_0 t} \text{ (absorb } V_0 \text{ by shifting the time origin). } \lambda_0 = 0.1733. \]

\[ T_0 = \frac{1}{\lambda_0} \ln(6.7 \times 10^7) = 103.8 \text{ months } = 8.65 \text{ years} \]

Let \( \gamma_0 = (2/3)\lambda_0 \) (leave from surface). First type 1 at \( \approx s_1 \) where

\[ 1 = \int_0^{s_1} u_1 e^{\gamma_0 t} \, dt \approx \frac{u_1}{\gamma_0} e^{\gamma_0 s_1} \]

If \( u_1 = e^{-a} \) solving gives \( s_1 = \frac{1}{\gamma_0}(a + \ln(\gamma_0)) = 8.65(a - 2.158) \)

\[ T_1 - s_1 = \frac{1}{\lambda_1} \ln(10^9) = 74.74 \text{ where } \lambda_1 = 0.2773 \]
Picking $u_1$

$T_0 = 103.8$, $T_1 - s_1 = 74.74$, $u_1 = e^{-a}$, $s_1 = 8.65 (a - 2.158)$

Size of primary at time $s_1$ is $0.04e^{3a/2}$ cells. During $[s_1, T_1]$ the size of the primary increases by a factor of

$$\exp(\lambda_0 (9 \cdot \ln 10)/\lambda_1) \approx 423,000$$

Brown and Palmer: mean size entering stage III is 3 cm. $1.4 \times 10^{10}$ cells.

When $u_1 = 10^{-4}$ the window $T_1 - T_0 = 2.66$ years.

Size of primary at $s_1$ is $4 \times 10^4$. (Too small?) Diameter $= 0.84$ mm.

Size at time $T_1$ is $1.68 \times 10^{10}$ in agreement with Brown and Palmer.
Primary tumor follows logistic growth?

Let $R = (3V/4\pi)^{1/3}$ be the tumor radius.

$$\frac{dV}{dt} = \lambda \int_0^R 4\pi r^2 f(R - r) \, dr$$

where $f(x)$ describes nutrient availability $x$ cm from the surface and $f(x) \downarrow 0$ exponentially fast as $x \uparrow \infty$.

$V(t)$ grows exponentially fast early but for large $t$,

$$V'(t) \sim BR^2 \quad \text{i.e.,} \quad V(t) \sim Ct^3.$$
Size of the Primary at $T_1 = \inf\{t : Z_1(t) > 10^9\}$

In the previous calculations we ignored the fact that $Z_1(t) \sim V_1 e^{-\lambda_1 t}$.

$$T_1 = \frac{1}{\lambda_1} \ln(10^9/V_1)$$

At this time

$$Z_0(T_1) = \exp(\lambda_0 T_1) = (10^9 V_1)^\alpha \quad \alpha = \lambda_0/\lambda_1$$

Brockwell and Brown (1978) ZfW (aka PTRF), $V_1^{-\alpha}$ has density

$$\sum_{k=0}^{\infty} \frac{(-x)^k}{\Gamma(k + 1)\Gamma(1 - \alpha - \alpha k)}$$
Probability of Progression vs. Size

![Graph showing probability of progression vs. tumor size]

- 25th Percentile
- Median
- 75th Percentile

Probability CIS, Stage I or Stage II

Tumor Diameter (mm)

$P(\text{transition})$

0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5

diameter(cm)
Use branching process model and a model of detection to predict incidence curve. Picture from Armitage and Doll. We will use SEER data.
Within Tumor Heterogeneity

Problems in cancer treatment caused by intra-tumor diversity:

- Different subpopulations within a tumor may have varying types of response to any given treatment, making total tumor reduction and prevention of resistance difficult.
- Heterogeneity levels are associated with aggressiveness of disease (e.g., in Barrett’s esophagus and prostate cancer).
- Studies have also shown mutational heterogeneity between primary tumors and metastases in breast cancer, explaining lack of response to EFGR antibody therapy in patients that appeared to have no mutation in KRAS.
Intra-tumor diversity generated by model

In this simulation, \( b_i = 0.1, \ a_0 = 0.2, \ a_i - a_{i-1} \sim U([0, 0.05]), \ u = 0.001. \)
Point process representation of $V_1$

$Z_0(t) = V_0 e^{\lambda_0 t}$, $V_0$ nonrandom.

Define a two dimensional point process $\mathcal{X}_t$ with a point at $(s, w)$ if there was a mutation to type 1 at time $s$ and the resulting type 1 branching process $\tilde{Z}_1(t)$ has $e^{-\lambda_1(t-s)}\tilde{Z}_1(t) \to w$.

A point at $(s, w)$ contributes $e^{-\lambda_1 s}w$ to $V_1 = \lim_{t \to \infty} e^{-\lambda_1 t}Z_1(t)$.

$V_1 = \sum_{(s, w) \in \mathcal{X}_t} e^{-\lambda_1 s}w$, the sum of points in a Poisson point process with mean measure $\mu(z, \infty) = A_1 u_1 V_0 z^{-\alpha}$ where $\alpha = \lambda_0/\lambda_1$.

True for $(V_k | \mathcal{F}_{k-1}^\infty)$ with $\alpha = \lambda_{k-1}/\lambda_k$. 

Rick Durrett (Duke)
Let $Y_1, Y_2, \ldots$ be independent and identically distributed nonnegative random variables with $P(Y_i > x) \sim cx^{-\alpha}$ with $0 < \alpha < 1$. Let $S_n = Y_1 + \cdots + Y_n$. Then

$$S_n/n^{1/\alpha} \to V$$

where $V$ is the sum of points in a Poisson process with mean measure $\mu(z, \infty) = cx^{-\alpha}$.
Simpson’s index

We define Simpson’s index to be the probability two randomly chosen individuals in wave $k$ are descended from the same mutation.

$$R = \sum_{i=1}^{\infty} \frac{X_i^2}{V_k^2}$$

where $X_1 > X_2 > \ldots$ are points in the Poisson process and $V_k$ is the sum.

**Theorem.** $ER = 1 - \alpha$ where $\alpha = \lambda_{k-1}/\lambda_k$ for wave $k$.

Proof. Apply results of Fuchs, Joffe and Teugels (2001) about convergence to stable laws. $ER$ does not depend on $V_{k-1}$.
Figure: Empirical distribution of Simpson’s Index for wave 1 at times $t = 70, 90, 110, 130, \infty$. Parameters: $b_i = 0.1$, $a_0 = 0.2$, $a_i - a_{i-1} \sim U([0, 0.01])$, mean is $1 - \alpha = 1/11$. 
Consider the “self-normalized sums”

\[ S_n(p) = \frac{\sum_{i=1}^{n} X_i}{\left(\sum_{j=1}^{n} X_j^p\right)^{1/p}} \quad S_n(2) = R_n^{-1/2} \]

They proved convergence in distribution and identified the Fourier transform of the limit.
The graph shows a function $f(x)$ with points marked at $f(\sqrt{2}) = 2.03$ and $f(\sqrt{3}) = 0.118$. The parameters are $p = 2$, $\alpha = 0.15$, and $L = 0$. The $x$-axis is labeled from 1.0 to 2.0, and the $y$-axis from 0.02 to 1.0.
Largest clone

Let $U_n = \max_{1 \leq i \leq n} Y_i / S_n$ be the contribution of the largest term to the sum.

**Darling (1952). Theorem 5.1.** As $n \to \infty$, $U_n^{-1} \to T$ where $T$ has characteristic function $e^{it} / f_{\alpha}(t)$ where

$$f_{\alpha}(t) = 1 + \alpha \int_0^1 (1 - e^{itu})u^{-(\alpha+1)} \, du$$

$ET = 1/(1 - \alpha)$ and $\text{var}(T) = 2/(1 - \alpha)^2(2 - \alpha)$. 
Figure: Monte Carlo estimates for $E(1/U_n)$ and $EU_n$ plotted versus $1/(1 - \alpha)$ and $1 - \alpha$. $T = \lim 1/U_n$ has $ET = 1/(1 - \alpha)$ and $E(1/T) > 1 - \alpha$. 
Growth, progression, and metastasis of cancer can be modeled with multi-type branching processes, and these models can be used to evaluate screening strategies and treatment regimens.

\( (e^{-\lambda_k t} Z_k(t)|\mathcal{F}_{k-1}^\infty) \rightarrow V_k \) where \( V_k \) is one-sided stable with index \( \alpha_k = \lambda_{k-1}/\lambda_k \).

Results about stable laws can be used to obtain results about tumor heterogeneity and other quantities of interest.

In contrast to simulation, our analytical results are exact, and reveal the dependence on underlying parameters.